Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Cancers attributable to human papillomavirus infection

Cancers attributable to human papillomavirus infection Although the human papillomavirus (HPV) vaccine was introduced primarily as a cervical cancer prevention vaccine, HPV has a causal role in several types of cancer. This article reviews the epidemiological evidence for the role of HPV in human cancer, and describes Australian trends in these cancers. HPV is a necessary cause of cervical cancer. The currently vaccine-preventable subtypes of HPV 16 and 18 are responsible for ~70% of cervical cancer. The introduction of an organised Pap smear program in Australia led to a steep decline in incidence over the past decades. HPV can be detected in ~40% and 70% of vulval and vaginal cancers respectively. Rates of these cancers have been stable over the past 20 years. The prevalence of HPV in penile cancer is ~50% and incidence has not recently changed. For anal cancer, ~85% of cases are HPV positive, and incidence has increased significantly in both men and women over the past 20 years. In the oral cavity, ~35% of oropharyngeal cancers and ~25% of other oral cavity cancers are HPV positive. The incidence of HPV-related oral cavity and oropharyngeal cancers is increasing, whereas incidence at HPV-unrelated sites is decreasing. Overall, 1154 HPV-related cancer cases were potentially preventable by vaccination. If HPV-related cancers at non-cervical sites are prevented by vaccination, then a similar number of cancer cases will be prevented as in the cervix. However, almost one-quarter of the potentially preventable cancer cases are in men, who are not included in the current national immunisation program. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Sexual Health CSIRO Publishing

Cancers attributable to human papillomavirus infection

Download PDF
9 pages

Loading next page...
 
/lp/csiro-publishing/cancers-attributable-to-human-papillomavirus-infection-t5URgQ74VR

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
CSIRO Publishing
Copyright
CSIRO
ISSN
1448-5028
eISSN
1449-8987
DOI
10.1071/SH10020
pmid
20719211
Publisher site
See Article on Publisher Site

Abstract

Although the human papillomavirus (HPV) vaccine was introduced primarily as a cervical cancer prevention vaccine, HPV has a causal role in several types of cancer. This article reviews the epidemiological evidence for the role of HPV in human cancer, and describes Australian trends in these cancers. HPV is a necessary cause of cervical cancer. The currently vaccine-preventable subtypes of HPV 16 and 18 are responsible for ~70% of cervical cancer. The introduction of an organised Pap smear program in Australia led to a steep decline in incidence over the past decades. HPV can be detected in ~40% and 70% of vulval and vaginal cancers respectively. Rates of these cancers have been stable over the past 20 years. The prevalence of HPV in penile cancer is ~50% and incidence has not recently changed. For anal cancer, ~85% of cases are HPV positive, and incidence has increased significantly in both men and women over the past 20 years. In the oral cavity, ~35% of oropharyngeal cancers and ~25% of other oral cavity cancers are HPV positive. The incidence of HPV-related oral cavity and oropharyngeal cancers is increasing, whereas incidence at HPV-unrelated sites is decreasing. Overall, 1154 HPV-related cancer cases were potentially preventable by vaccination. If HPV-related cancers at non-cervical sites are prevented by vaccination, then a similar number of cancer cases will be prevented as in the cervix. However, almost one-quarter of the potentially preventable cancer cases are in men, who are not included in the current national immunisation program.

Journal

Sexual Health – CSIRO Publishing

Published: Aug 19, 2010

Keywords: Australia, cervical cancer, HPV vaccine.

References

  • A review of human carcinogens – part B: biological agents.
    Bouvard V
  • Prophylactic HPV vaccines: new interventions for cancer control.
    Barr E
  • Carcinogenicity of human papillomaviruses.
    Cogliano V
  • Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States.
    Chaturvedi AK
  • Global Cancer Statistics, 2002.
    Parkin D
  • Cervical cancer prevention: the saga goes on, but so much has changed!
    Wain GV
  • Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection.
    Franco EL
  • Age distribution of human papillomavirus infection and cervical neoplasia reflects caveats of cervical screening policies.
    Chan PK
  • Incidence, duration and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results.
    Muñoz N
  • Variations in the age-specific curves of human papillomavirus prevalence in women worldwide.
    Franceschi S
  • Prevalence of oncogenic human papillomavirus infection in an organised screening population in Finland.
    Leinonen M
  • Cancer incidence and survival for Indigenous Australians in the Northern Territory.
    Condon J
  • Improvements in the protection against adenocarcinoma of the cervix from participation in cervical screening.
    Mitchell H
  • Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.
    Walboomers JM
  • How much cervical cancer in Australia is vaccine preventable? A meta-analysis.
    Brotherton JM
  • Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis.
    Clifford G
  • Human papillomavirus and cervical cancer in Australasia and Oceania: risk-factors, epidemiology and prevention.
    Garland SM
  • Smoking and cervical cancer: current status – a review.
    Winkelstein W
  • Neoplasia of the uterine cervix and contraception: a possible adverse effect of the pill.
    Vessey M
  • Examining the association between socioeconomic status and potential human papillomavirus-associated cancers.
    Benard VB
  • Risk of human papillomavirus-associated cancers among people with AIDS.
    Chaturvedi AK
  • Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis.
    Grulich A
  • Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis.
    De Vuyst H
  • A cluster of vulvar cancer and vulvar intraepithelial neoplasia in young Australian Indigenous women.
    Condon JR
  • Impact of human
    Munoz N
  • Systematic review of human papillomavirus prevalence in invasive penile cancer.
    Backes DM
  • Penile cancer: epidemiology, pathogenesis and prevention.
    Bleeker MC
  • Human papillomavirus prevalence and type distribution in penile carcinoma.
    Miralles-Guri C
  • Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa.
    Auvert B
  • Understanding the burden of human papillomavirus-associated anal cancers in the US.
    Joseph DA
  • Human papillomavirus vaccines and anal carcinoma.
    Franceschi S
  • An analysis of temporal and generational trends in the incidence of anal and other HPV-related cancers in Southeast England.
    Robinson D
  • Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions.
    Hoots BE
  • Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer.
    Daling JR
  • Anal human papillomavirus genotype diversity and co-infection in a community-based sample of homosexual men.
    Vajdic CM
  • Sexual practices, sexually transmitted diseases, and the incidence of anal cancer.
    Daling JR
  • Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis.
    Grulich AE
  • Human papillomavirus-related disease in people with HIV.
    Palefsky J
  • Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy.
    van Leeuwen MT
  • Is screening for anal cancer warranted in homosexual men?
    Anderson JS
  • Burden and trends of type-specific human papillomavirus infections and related diseases in the Asia Pacific region.
    Parkin DM
  • Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998–2003.
    Ryerson AB
  • Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers?
    Sturgis EM
  • Changing patterns of tonsillar squamous cell carcinoma in the United States.
    Frisch M
  • Incidence of human
    Näsman A
  • Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review.
    Kreimer AR
  • HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1988–2007).
    Termine N
  • Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis.
    Ragin CC
  • Case-control study of human papillomavirus and oropharyngeal cancer.
    D’Souza G
  • Oral sexual behaviors associated with prevalent oral human papillomavirus infection.
    D’Souza G
  • Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers.
    Gillison ML
  • Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9–10, 2008, Washington, D.C.
    Adelstein DJ
  • HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women.
    Gillison ML